glioma
Conditions
Interventions
Sponsors
First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
1 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.Diagnosis: All enrolled patients must be histopathologically confirmed with glioma by a pathologist. 2.Follow-up Duration: All participants must undergo at least one follow-up evaluation (with a minimum follow-up period of 6 months from baseline) to ensure data completeness and accuracy. 3.Telephone Informed Consent: All participants must voluntarily agree to participate in the study. For patients who lack sufficient comprehension and decision-making capacity due to their medical condition or age, a legal guardian shall determine their participation. Given the retrospective nature of this study, informed consent must be obtained via telephone to ensure adherence to ethical guidelines. 4.Inclusion Timeframe: January 1, 2010, to November 30, 2025. 5.Age Range: 1 to 90 years of age.
Exclusion criteria
Exclusion criteria: 1.History of Other Malignancies: Patients with a previous history of other types of malignant tumors (to avoid potential confounding effects). 2.Missing/Incomplete Data: Patients who lack complete data on blood biochemical parameters and body composition will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS);progression-free survival (PFS);recurrence-free survival (RFS);Advances in Pathology; | — |
Countries
China
Contacts
Public ContactTian Hui
First Affiliated Hospital of Kunming Medical University
Outcome results
None listed